Center for Personalized Medicine, South Texas Veterans Health Care System, San Antonio, Texas, United States of America.
PLoS One. 2012;7(11):e49498. doi: 10.1371/journal.pone.0049498. Epub 2012 Nov 16.
CC chemokine ligand 2 (CCL2) is the most potent monocyte chemoattractant and inter-individual differences in its expression level have been associated with genetic variants mapping to the cis-regulatory regions of the gene. An A to G polymorphism in the CCL2 enhancer region at position -2578 (rs1024611; A>G), was found in most studies to be associated with higher serum CCL2 levels and increased susceptibility to a variety of diseases such as HIV-1 associated neurological disorders, tuberculosis, and atherosclerosis. However, the precise mechanism by which rs1024611influences CCL2 expression is not known. To address this knowledge gap, we tested the hypothesis that rs1024611G polymorphism is associated with allelic expression imbalance (AEI) of CCL2. We used haplotype analysis and identified a transcribed SNP in the 3'UTR (rs13900; C>T) can serve as a proxy for the rs1024611 and demonstrated that the rs1024611G allele displayed a perfect linkage disequilibrium with rs13900T allele. Allele-specific transcript quantification in lipopolysaccharide treated PBMCs obtained from heterozygous donors showed that rs13900T allele were expressed at higher levels when compared to rs13900C allele in all the donors examined suggesting that CCL2 is subjected to AEI and that that the allele containing rs1024611G is preferentially transcribed. We also found that AEI of CCL2 is a stable trait and could be detected in newly synthesized RNA. In contrast to these in vivo findings, in vitro assays with haplotype-specific reporter constructs indicated that the haplotype bearing rs1024611G had a lower or similar transcriptional activity when compared to the haplotype containing rs1024611A. This discordance between the in vivo and in vitro expression studies suggests that the CCL2 regulatory region polymorphisms may be functioning in a complex and context-dependent manner. In summary, our studies provide strong functional evidence and a rational explanation for the phenotypic effects of the CCL2 rs1024611G allele.
CC 趋化因子配体 2(CCL2)是最有效的单核细胞趋化因子,其表达水平的个体差异与基因顺式调控区域的遗传变异有关。在大多数研究中,CCL2 增强子区域位置-2578 处的 A 到 G 多态性(rs1024611;A>G)与更高的血清 CCL2 水平和增加易患各种疾病(如 HIV-1 相关神经障碍、结核病和动脉粥样硬化)相关。然而,rs1024611 影响 CCL2 表达的确切机制尚不清楚。为了解决这一知识空白,我们检验了 rs1024611G 多态性与 CCL2 等位基因表达失衡(AEI)相关的假设。我们使用单倍型分析并确定了 3'UTR 中的一个转录 SNP(rs13900;C>T)可作为 rs1024611 的替代物,并证明 rs1024611G 等位基因与 rs13900T 等位基因完美连锁不平衡。从杂合供体的 LPS 处理的 PBMCs 中进行的等位基因特异性转录定量显示,与 rs13900C 等位基因相比,所有检测到的供体中的 rs13900T 等位基因表达水平更高,表明 CCL2 受到 AEI 的影响,并且含有 rs1024611G 的等位基因优先转录。我们还发现,CCL2 的 AEI 是一种稳定的特征,可以在新合成的 RNA 中检测到。与这些体内发现相反,具有特定单倍型的报告基因构建体的体外测定表明,与含有 rs1024611A 的单倍型相比,携带 rs1024611G 的单倍型的转录活性较低或相似。这些体内和体外表达研究之间的差异表明,CCL2 调节区多态性可能以复杂和依赖于上下文的方式发挥作用。总之,我们的研究为 CCL2 rs1024611G 等位基因的表型效应提供了强有力的功能证据和合理的解释。